191 related articles for article (PubMed ID: 32913556)
1. Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases.
In GK; Poorman K; Saul M; O'Day S; Farma JM; Olszanski AJ; Gordon MS; Thomas JS; Eisenberg B; Flaherty L; Weise A; Daveluy S; Gibney G; Atkins MB; Vanderwalde A
Oncotarget; 2020 Aug; 11(33):3118-3128. PubMed ID: 32913556
[TBL] [Abstract][Full Text] [Related]
2. Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.
In GK; Ribeiro JR; Yin J; Xiu J; Bustos MA; Ito F; Chow F; Zada G; Hwang L; Salama AKS; Park SJ; Moser JC; Darabi S; Domingo-Musibay E; Ascierto ML; Margolin K; Lutzky J; Gibney GT; Atkins MB; Izar B; Hoon DSB; VanderWalde AM
NPJ Precis Oncol; 2023 Nov; 7(1):120. PubMed ID: 37964004
[TBL] [Abstract][Full Text] [Related]
3. Melanoma brain metastases harboring BRAF
Fang P; Boehling NS; Koay EJ; Bucheit AD; Jakob JA; Settle SH; Brown PD; Davies MA; Sulman EP
J Neurooncol; 2018 Mar; 137(1):67-75. PubMed ID: 29198052
[TBL] [Abstract][Full Text] [Related]
4. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
5. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?
Gampa G; Vaidhyanathan S; Sarkaria JN; Elmquist WF
Pharmacol Res; 2017 Sep; 123():10-25. PubMed ID: 28634084
[TBL] [Abstract][Full Text] [Related]
6. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
[TBL] [Abstract][Full Text] [Related]
7. Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R; Vordermark D; Hassel JC; Krex D; Wendl C; Schadendorf D; Sickmann T; Rieken S; Pukrop T; Höller C; Eigentler TK; Meier F
Cancer Treat Rev; 2020 Sep; 89():102083. PubMed ID: 32736188
[TBL] [Abstract][Full Text] [Related]
8. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
10. Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.
Weiss SA; Zito C; Tran T; Heishima K; Neumeister V; McGuire J; Adeniran A; Kluger H; Jilaveanu LB
J Neurooncol; 2021 Mar; 152(1):15-25. PubMed ID: 32974852
[TBL] [Abstract][Full Text] [Related]
11. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
Fischer GM; Jalali A; Kircher DA; Lee WC; McQuade JL; Haydu LE; Joon AY; Reuben A; de Macedo MP; Carapeto FCL; Yang C; Srivastava A; Ambati CR; Sreekumar A; Hudgens CW; Knighton B; Deng W; Ferguson SD; Tawbi HA; Glitza IC; Gershenwald JE; Vashisht Gopal YN; Hwu P; Huse JT; Wargo JA; Futreal PA; Putluri N; Lazar AJ; DeBerardinis RJ; Marszalek JR; Zhang J; Holmen SL; Tetzlaff MT; Davies MA
Cancer Discov; 2019 May; 9(5):628-645. PubMed ID: 30787016
[TBL] [Abstract][Full Text] [Related]
12. Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
Sharma G; Lian CG; Lin WM; Amin-Mansour A; Jané-Valbuena J; Garraway L; Bao W; Yoon CH; Ibrahim N
J Cutan Pathol; 2016 Oct; 43(10):884-91. PubMed ID: 27251777
[TBL] [Abstract][Full Text] [Related]
13. Advances in the systemic treatment of melanoma brain metastases.
Glitza Oliva IC; Schvartsman G; Tawbi H
Ann Oncol; 2018 Jul; 29(7):1509-1520. PubMed ID: 29790899
[TBL] [Abstract][Full Text] [Related]
14. Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma.
Váraljai R; Horn S; Sucker A; Piercianek D; Schmitt V; Carpinteiro A; Becker KA; Reifenberger J; Roesch A; Felsberg J; Reifenberger G; Sure U; Schadendorf D; Helfrich I
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33578810
[TBL] [Abstract][Full Text] [Related]
15. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.
Alvarez-Breckenridge C; Markson SC; Stocking JH; Nayyar N; Lastrapes M; Strickland MR; Kim AE; de Sauvage M; Dahal A; Larson JM; Mora JL; Navia AW; Klein RH; Kuter BM; Gill CM; Bertalan M; Shaw B; Kaplan A; Subramanian M; Jain A; Kumar S; Danish H; White M; Shahid O; Pauken KE; Miller BC; Frederick DT; Hebert C; Shaw M; Martinez-Lage M; Frosch M; Wang N; Gerstner E; Nahed BV; Curry WT; Carter B; Cahill DP; Boland GM; Izar B; Davies MA; Sharpe AH; Suvà ML; Sullivan RJ; Brastianos PK; Carter SL
Cancer Immunol Res; 2022 Aug; 10(8):996-1012. PubMed ID: 35706413
[TBL] [Abstract][Full Text] [Related]
16. Pathologic and gene expression features of metastatic melanomas to the brain.
Hamilton R; Krauze M; Romkes M; Omolo B; Konstantinopoulos P; Reinhart T; Harasymczuk M; Wang Y; Lin Y; Ferrone S; Whiteside T; Bortoluzzi S; Werley J; Nukui T; Fallert-Junecko B; Kondziolka D; Ibrahim J; Becker D; Kirkwood J; Moschos S
Cancer; 2013 Aug; 119(15):2737-46. PubMed ID: 23695963
[TBL] [Abstract][Full Text] [Related]
17. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
18. Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
Doma V; Kárpáti S; Rásó E; Barbai T; Tímár J
BMC Cancer; 2019 Aug; 19(1):786. PubMed ID: 31391014
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
20. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
